All agenda timings below are displayed in EDT. For PDT, please download the full program here.

Day Two

WEDNESDAY, SEPTEMBER 30

10:00 am Virtual Coffee Networking

10:25 am Chair’s Opening Remarks

Challenges With Data & Implementation

10:30 am Panel: Integration Within the Pharmaceutical Community

  • David Anstatt Executive Director, Center for Observational Research & Data Sciences, Bristol-Myers Squibb
  • Michael Lees Head of Value, Evidence and Portfolio Strategy, Takeda
  • Ipek Stillman Head, Globak Health Economics, Takeda

Synopsis

  • Big players in the field discuss their issues in company structure to compare bottlenecks and advantages

11:15 am Strategic Vision for RWE Generation Across the Product Lifecycle

Synopsis

  • Examining evidence generation as a key deliverable and an important strategic capability to enable efficient drug development and commercialization across the product lifecycle
  • Discussing the importance of understanding RWE approaches to address key questions, and an aligned leadership structure that embraces cross-functional trust, collaboration and communication
  • Defining the challenges impeding the full realization of benefit from RWE and opportunities to better ensure that needed evidence is generated

11:45 am Morning Break & Networking

12:30 pm Synthea: Augmenting RWD & Synthetic Data into a Limitless Platform

Synopsis

  • Presenting an introduction to Synthea – a synthetic universe
  • Augmenting clinical data for insight discovery
  • Reimagining AI and ML testing with synthetic data

1:00 pm Considerations for integrating digital and sensor data into the RWD ecosystem

Synopsis

  • Opportunities and challenges in data generated by remote monitoring systems
  • Augmenting real-world patient data with open-source public data
  • Personalizing RWE with AI

1:30 pm Lunch & Networking

2:30 pm What is Normal? Using AI to Normalize & Control the Quality of Data Outputs

  • Kevin Francis Principal - Head of RWE, Insights & Analytics, Trinity

Synopsis

  • Advanced computing to address the increasingly available and ever-growing big data
  • Different ways to use this technology to improve efficiency and outcomes of research
  • How it can improve business opportunities and drive growth in the future

Optimizing Post-Clinical Commercial Success

3:00 pm Strategizing Market Access – Ensuring Implementation for the Whole of the Drug Development Continuum

Synopsis

  • Comparing the differences between Medical Affairs and Market Access departments
  • Describing the transition from European to global outreach

3:30 pm Afternoon Break & Networking

4:00 pm Global Medical Affairs (GMA): Lessons Learnt from Creating a Department

  • Amy Place Senior Director, Field Medical Affairs, Scholar Rock

Synopsis

  • Revealing the plans and impact of building out a GMA branch
  • Recollecting on current observations and future challenges
  • Detailing personal accounts of introducing and incorporating GMA into trial design

4:30 pm Understanding Market Access Methodology

  • Omar Ali Pharmacist Consultant, QIPP Adviser Payer Network

Synopsis

  • Ensuring real world data effectiveness at other ends of the value chain
  • How to realize the full potential and seize the opportunity RWE presents
  • RWE usage perspectives of pharma and payers and how this will change in the next few years

5:00 pm Chair’s Closing Remarks & End of Conference